# Christoph Ruedig

> Christoph Ruedig is a Series A investor at AlbionVC (London) backing Health Care and Medical. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [AlbionVC](https://shizune.co/investors/profile/albion-vc)
- Location: London, United Kingdom
- Total investments: 12
- Last investment: Jan 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/cruedig/
- Website: https://x.com/ChristophRuedig
- Facebook: https://www.facebook.com/christoph.ruedig

Christoph Ruedig is a Series A investor at AlbionVC in London focused on Health Care and Medical. Christoph Ruedig is based out of London, England, and is the Partner of AlbionVC and Board Member of Evaro. Christoph previously worked at Cisiv as a Board Observer. Christoph Ruedig attended INSEAD.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 50% |
| Medical | 4 | 33% |
| mHealth | 2 | 17% |
| Software | 2 | 17% |
| Life Science | 2 | 17% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 58% |
| Seed | 2 | 17% |
| Series B | 1 | 8% |
| Series C | 1 | 8% |
| Funding Round | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 6 | 50% |
| Switzerland | 1 | 8% |
| United States | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Evaro | Evaro provides digital health integration to increase accessibility of pharmacy products. | $25M | Series A | Jan 26, 2026 |  |
| Umedeor | uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries. This enables sites to participate in dozens of programmes simultaneously without increasing overhead or burden on staff. For life science companies, uMed provides access toregulator quality data, where patients within those datasets can be compliantly re-engaged to support the aims of R&D and post-market teams | $12.8M | Series A | Jul 05, 2023 |  |
| PeakData | PeakData is a software platform to identify and analyze key opinion leaders in your therapeutic area. PeakData is making sense of the data spread across the web by using the latest developments of AI. | $12.4M | Series A | Aug 22, 2022 |  |
| Oviva | Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). | $80M | Series C | Aug 31, 2021 |  |
| NuvoAir | NuvoAir Medical is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions. NuvoAir’s care model integrates advanced monitoring technology and analytics with evidence-based interventions, all delivered by a multidisciplinary team. This approach ensures that each patient'sjourney is highly personalized. Collaborating with health plans and risk-bearing entities through flexible, value-based payment arrangements, NuvoAir distinguishes itself as a specialty care provider, effectively reducing healthcare costs and enhancing overall outcomes. | $12M | Series A | Jun 22, 2021 |  |
| Umedeor | uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries. This enables sites to participate in dozens of programmes simultaneously without increasing overhead or burden on staff. For life science companies, uMed provides access toregulator quality data, where patients within those datasets can be compliantly re-engaged to support the aims of R&D and post-market teams | $4.8M | Seed | Dec 01, 2020 |  |
| Umedeor | uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries. This enables sites to participate in dozens of programmes simultaneously without increasing overhead or burden on staff. For life science companies, uMed provides access toregulator quality data, where patients within those datasets can be compliantly re-engaged to support the aims of R&D and post-market teams | $4.8M |  | Dec 01, 2020 |  |
| Oviva | Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). | $21M | Series B | Jan 15, 2020 |  |
| Epsilogen | IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $6.5M | Series A | Nov 30, 2018 |  |
| Xperiome | Xperiome is a global healthtech company that helps pharma get to know rare disease patients and their conditions faster by delivering deep insights into the patient experience. We created Raremark as the place for the lived experience of rare disease. This data-driven knowledge bank of the rare experience allows us to match research-ready membersto clinical and real-world studies, faster and smarter than ever before. | $3.8M | Series A | Oct 22, 2018 |  |

10 of 12 investments shown.

## Co-investors
- [11.2 Capital](https://shizune.co/investors/profile/112capital) — VC Fund, 3 deals together
- [Delin Ventures](https://shizune.co/investors/profile/delin-ventures) — VC Fund, 3 deals together
- [Playfair Capital](https://shizune.co/investors/profile/playfair-capital) — VC Fund, 3 deals together
- [Earlybird Venture Capital](https://shizune.co/investors/profile/earlybird-venture-capital) — VC Fund, 2 deals together
- [Eight Roads Ventures](https://shizune.co/investors/profile/eight-roads-ventures) — VC Fund, 2 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 2 deals together

## About AlbionVC

VC Fund · London, United Kingdom

AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/

5 contacts available at AlbionVC.

| Name | Title | Profile |
| --- | --- | --- |
| Adam Chirkowski | Partner | https://shizune.co/investors/profile/adam-chirkowski |
| Christoph Ruedig | Partner | https://shizune.co/investors/profile/christoph-ruedig |
| Ed Lascelles | Partner | https://shizune.co/investors/profile/ed-lascelles |
| Andrew Elder | Deputy Managing Partner | https://shizune.co/investors/profile/andrew-elder |
| Cat McDonald | Investment Manager | https://shizune.co/investors/profile/cat-mcdonald |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Christoph Ruedig invest in?

Christoph Ruedig invests primarily in Health Care, Medical and mHealth startups, most often at Series A and Seed stage. Most of the 12 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Christoph Ruedig last invest?

The most recent investment recorded for Christoph Ruedig closed in Jan 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co